ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,933Medicare Part D Prescriptions Filled, Including Refills

Rank: 72 out of 337

$644K Total Retail Price of All Prescriptions

Rank: 37 out of 337

460 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
61% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 460 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

8% of this provider’s 460 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

0% of this provider’s 8,858 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$65 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
LISINOPRIL 341 311 1 2
FUROSEMIDE 327 304 2 8
TRAZODONE HCL 318 287 3 16
WARFARIN SODIUM 313 282 4 11
METOPROLOL TARTRATE 272 260 5 6
LOVASTATIN 270 250 6 24
LEVOTHYROXINE SODIUM 265 244 7 5
MIRTAZAPINE 165 151 8 27
DONEPEZIL HCL 142 142 9 22
RANITIDINE HCL 140 137 10 30
SERTRALINE HCL 136 136 11 18
SIMVASTATIN 134 130 12 1
CHLORTHALIDONE 128 128 13 117
LANTUS 127 102 14 49
ATENOLOL 124 121 15 10
CYMBALTA 118 99 16 59
FINASTERIDE 116 95 17 83
AMLODIPINE BESYLATE 113 107 18 3
PREDNISONE 112 103 19 40
CRESTOR 110 110 20 29
ALLOPURINOL 109 105 21 28
DOXAZOSIN MESYLATE 107 93 22 68
NAMENDA 103 103 23 35
LOSARTAN POTASSIUM 100 96 24 15
RISPERIDONE 99 88 25 72
CITALOPRAM HBR 99 91 25 17
NOVOLOG 97 78 27 106
OXYCODONE HCL 96 49 S2 28 63
HYDROCHLOROTHIAZIDE 95 77 29 9
METFORMIN HCL 94 76 30 12
ATORVASTATIN CALCIUM 91 73 31 7
HYDROCODONE-ACETAMINOPHEN 88 74 S3 32 13
TAMSULOSIN HCL 86 82 33 25
PRAVASTATIN SODIUM 80 79 34 14
GABAPENTIN 78 57 35 20
METOPROLOL SUCCINATE 78 75 35 21
MELOXICAM 75 63 37 54
DIGOXIN 73 73 38 58
ESCITALOPRAM OXALATE 71 71 39 66
ADVAIR DISKUS 71 61 39 44
COLCRYS 69 65 41 128
BACLOFEN 62 35 42 133
SPIRIVA 61 61 43 43
DIOVAN 60 60 44 26
CARVEDILOL 59 59 45 73
CLOTRIMAZOLE 59 52 45 227
OMEPRAZOLE 58 58 47 4
LEVETIRACETAM 57 37 48 112
CLOPIDOGREL 56 47 49 42
EVISTA 53 53 50 102
TRAMADOL HCL 52 51 51 32
OXYCONTIN 52 23 S2 51 87
KLOR-CON M10 51 51 53 162
AZITHROMYCIN 50 46 54 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 10, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.